 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || modafinil / Generic mfg., irdabisant (CEP-26401) / Teva, donepezil / Generic mfg.
Clinical, Journal: Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers. (Pubmed Central) - May 15, 2020
Of the doses tested, the 25 μg dose of CEP-26401 had the most optimal balance between favourable subjective effects and sleep inhibition. Whether CEP-26401 can have beneficial effects in clinical practice remains to be studied.
- | irdabisant (CEP-26401) / Teva
Trial completion: Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects (clinicaltrials.gov) - Apr 1, 2014
P1, N=40, Completed, Sponsor: Teva Pharmaceutical Industries
Whether CEP-26401 can have beneficial effects in clinical practice remains to be studied. Active, not recruiting --> Completed
- | irdabisant (CEP-26401) / Teva
New P1 trial: Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects (clinicaltrials.gov) - Jul 17, 2013
P1, N=40, Completed, Sponsor: Teva Pharmaceutical Industries